Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 19.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 317,329 shares of the company's stock after purchasing an additional 52,360 shares during the period. The Manufacturers Life Insurance Company owned 0.24% of Centessa Pharmaceuticals worth $5,315,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CNTA. Boothbay Fund Management LLC acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth $702,000. Lord Abbett & CO. LLC grew its holdings in shares of Centessa Pharmaceuticals by 63.6% during the fourth quarter. Lord Abbett & CO. LLC now owns 440,495 shares of the company's stock worth $7,378,000 after buying an additional 171,290 shares in the last quarter. Voya Investment Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $497,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Centessa Pharmaceuticals by 22.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock valued at $85,744,000 after buying an additional 924,027 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after acquiring an additional 685,371 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CNTA. Guggenheim reissued a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley restated an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Piper Sandler began coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of "Buy" and an average price target of $27.71.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $12.08 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09. The stock's 50 day moving average price is $14.00 and its 200 day moving average price is $15.72. The firm has a market capitalization of $1.61 billion, a PE ratio of -7.90 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, sell-side analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the transaction, the chief executive officer now owns 331,017 shares of the company's stock, valued at $5,273,100.81. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Karen M. Anderson sold 30,526 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the completion of the transaction, the insider now owns 54,322 shares of the company's stock, valued at approximately $1,033,747.66. The trade was a 35.98 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 202,353 shares of company stock valued at $3,286,478. 11.59% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.